menu
    • menu

    Company profile for Omeros

    NEW Drugs in Dev: 10
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    We have taken a similar approach in structuring our company. While many biotechs pursue a single therapeutic area or scientific platform, we are strategically building a deep and diverse pipeline of first-in-class small-molecule and antibody therapeutics. The strength of our scientific discoveries and exclusive intellectual property positions enable our pipeline programs to target highly promising receptors and enzymes that ot...
    We have taken a similar approach in structuring our company. While many biotechs pursue a single therapeutic area or scientific platform, we are strategically building a deep and diverse pipeline of first-in-class small-molecule and antibody therapeutics. The strength of our scientific discoveries and exclusive intellectual property positions enable our pipeline programs to target highly promising receptors and enzymes that others have not been able to develop.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    OmerosUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    The Omeros Building, 201 Elliott Avenue, West Seattle, WA 98119
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.omeros.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/omeros-corporation
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/omeroscorp?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    Asia Pharma Expo

    Not Confirmed

    envelop Contact Supplier

    Asia Pharma Expo

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Omeros Corp To Release 2025 Financial Results On March 31, 2026
    Omeros Corp To Release 2025 Financial Results On March 31, 2026

    26 Mar 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-03-26/omeros-corporation-to-announce-fourth-quarter-and-full-year-2025-financial-results-on-march-31-2026

    PHARMIWEB
    26 Mar 2026
    Share Share
    Omeros To Present Advances In TA-TMA Treatment At EBMT 2026
    Omeros To Present Advances In TA-TMA Treatment At EBMT 2026

    23 Mar 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260321749459/en/Omeros-Announces-Upcoming-Presentation-at-EBMT-2026-Highlighting-Advances-in-TA-TMA-Treatment

    BUSINESSWIRE
    23 Mar 2026
    Share Share
    Omeros Reports Primate Study Success In Oncotox-AML Program
    Omeros Reports Primate Study Success In Oncotox-AML Program

    17 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260217464206/en/Omeros-Announces-Successful-Primate-Study-in-OncotoX-AML-Drug-Program

    BUSINESSWIRE
    17 Feb 2026
    Share Share
    Omeros Announces First Commercial Sales of Yartemlea
    Omeros Announces First Commercial Sales of Yartemlea

    27 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260127787283/en/Omeros-Announces-First-Commercial-Sales-of-YARTEMLEA

    BUSINESSWIRE
    27 Jan 2026
    Share Share
    FDA approves Omeros' drug to treat transplant complication
    FDA approves Omeros' drug to treat transplant complication

    24 Dec 2025

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-omeros-drug-treat-dangerous-transplant-complication-2025-12-24/

    REUTERS
    24 Dec 2025
    Share Share
    Omeros Closes Deal With Novo Nordisk For MASP-3 Inhibitor OMS906
    Omeros Closes Deal With Novo Nordisk For MASP-3 Inhibitor OMS906

    01 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251201875667/en/Omeros-Corporation-Announces-Closing-of-Asset-Purchase-and-License-Agreement-with-Novo-Nordisk-for-Omeros-Clinical-Stage-MASP-3-Inhibitor-Zaltenibart-OMS906

    BUSINESSWIRE
    01 Dec 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search